Johns Hopkins Kimmel Cancer Center
Higher mutational burdens in tumours linked to greater immunotherapy success, study finds
December 21, 2017Research and Development Cancer, Johns Hopkins Kimmel Cancer Center, checkpoint inhibitors, mutational burden, pharma
New research from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Cancer Institute for Cancer Immunotherapy has indicated that …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
